Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.860
+0.240 (6.63%)
At close: Aug 28, 2026, 4:00 PM EDT
3.820
-0.040 (-1.04%)
After-hours: Aug 28, 2026, 7:30 PM EDT
Rocket Pharmaceuticals Employees
Rocket Pharmaceuticals had 202 employees as of December 31, 2025. The number of employees decreased by 97 or -32.44% compared to the previous year.
Employees
202
Change (1Y)
-97
Growth (1Y)
-32.44%
Revenue / Employee
n/a
Profits / Employee
-$85,396
Market Cap
423.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 202 | -97 | -32.44% |
| Dec 31, 2024 | 299 | 31 | 11.57% |
| Dec 31, 2023 | 268 | 28 | 11.67% |
| Dec 31, 2022 | 240 | 89 | 58.94% |
| Dec 31, 2021 | 151 | 60 | 65.93% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsRCKT News
- 19 days ago - Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush - TheFly
- 20 days ago - Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c - TheFly
- 20 days ago - Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress - Business Wire
- 20 days ago - Rocket Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 20 days ago - Rocket Pharmaceuticals Earnings release: Q2 2026 - Filings
- 27 days ago - Rocket announces safety update from three patients treated with RP-A501 - TheFly
- 27 days ago - Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business Wire
- 2 months ago - Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M - TheFly